Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
94.269,55
0,11%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX) Notizie

Edgewise Therapeutics Inc

EWTX
28,74
-0,92 (-3,10%)
28 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/12/202423:25EDGAR2Form 8-K - Current report
16/12/202412:00BWEdgewise Therapeutics Announces Positive Topline Results..
05/12/202420:32BWEdgewise Provides Statement Regarding Company’s Relationship..
26/11/202412:00BWEdgewise Therapeutics to Present at the Piper Sandler 36th..
07/11/202414:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/11/202414:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202414:00EDGAR2Form 8-K - Current report
07/11/202414:00BWEdgewise Therapeutics Reports Third Quarter 2024 Financial..
01/10/202414:00BWEdgewise Therapeutics to Present on Sevasemten (EDG-5506)..
25/9/202402:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202402:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202422:46EDGAR2Form 144 - Report of proposed sale of securities
20/9/202422:29EDGAR2Form 144 - Report of proposed sale of securities
19/9/202413:00BWEdgewise Therapeutics Announces Positive Top-Line Data from..
17/9/202422:01BWEdgewise Therapeutics to Host Webcast Event to Discuss..
14/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202423:07EDGAR2Form 8-K - Current report
08/8/202414:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202414:00EDGAR2Form 8-K - Current report
08/8/202414:00BWEdgewise Therapeutics Reports Second Quarter 2024 Financial..
13/6/202401:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202415:10EDGAR2Form 8-K - Current report
10/5/202415:07EDGAR2Form S-3ASR - Automatic shelf registration statement of..
10/5/202414:00BWEdgewise Therapeutics to Present at the RBC Capital Markets..
09/5/202415:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202414:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202414:00EDGAR2Form 8-K - Current report
09/5/202414:00BWEdgewise Therapeutics Reports First Quarter 2024 Financial..
07/5/202415:16EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/5/202415:14EDGAR2Form 8-K - Current report
07/5/202414:00BWEdgewise Therapeutics Appoints Arlene Morris to its Board of..
06/5/202414:00BWEdgewise Therapeutics Doses First Patient in Phase 2..
23/4/202414:00BWEdgewise Receives European Medicines Agency (EMA) Orphan..
15/4/202422:05BWEdgewise Therapeutics Announces Positive Two-Year Topline..
28/3/202413:00BWEdgewise Therapeutics Announces Upcoming Podium Presentation..
27/3/202413:00BWEdgewise Therapeutics to Present at the Cantor Virtual..
05/3/202414:00BWEdgewise Therapeutics to Present at the Leerink Partners..
28/2/202414:00BWEdgewise Therapeutics to Present on EDG-5506 for the..
22/2/202414:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202414:00EDGAR2Form 8-K - Current report
22/2/202414:00BWEdgewise Therapeutics Reports Fourth Quarter and Full Year..
14/2/202414:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:00BWEdgewise Receives U.S. FDA Fast Track Designation for..
09/2/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:15EDGAR2Form 144 - Report of proposed sale of securities
19/1/202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202414:44EDGAR2Form 8-K - Current report
19/1/202414:37BWEdgewise Therapeutics Announces Pricing of $240 Million..
19/1/202412:05EDGAR2Form 8-K - Current report
Apertura: 29,46 Min: 28,37 Max: 29,86
Chiusura: 29,66

La tua Cronologia

NASDAQ
EWTX
Edgewise Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network